+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

From
ABBV-951 Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

ABBV-951 Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
Myotonic Dystrophy - Pipeline Insight, 2024 - Product Thumbnail Image

Myotonic Dystrophy - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 80 Pages
  • Global
From
From
Sensorineural Hearing Loss - Pipeline Insight, 2024 - Product Thumbnail Image

Sensorineural Hearing Loss - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 50 Pages
  • Global
From
Huntington's Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Huntington's Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 150 Pages
  • Global
From
X linked Adrenoleukodystrophy - Pipeline Insight, 2024 - Product Thumbnail Image

X linked Adrenoleukodystrophy - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
West Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

West Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Status Epilepticus - Pipeline Insight, 2024 - Product Thumbnail Image

Status Epilepticus - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Plexiform neurofibroma - Pipeline Insight, 2024 - Product Thumbnail Image

Plexiform neurofibroma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Dup15q Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Dup15q Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Dyskinesia - Pipeline Insight, 2024 - Product Thumbnail Image

Dyskinesia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Diabetic Neuropathic Pain - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Neuropathic Pain - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Primary Progressive Aphasia - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Progressive Aphasia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Refractory Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Tay-Sachs Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Tay-Sachs Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
NE-3107 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

NE-3107 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
From
BIIB-122 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

BIIB-122 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more